TY - JOUR
T1 - Quantitative analysis of drug distribution in heterogeneous tissues using dual-stacking capillary electrophoresis–mass spectrometry
AU - Koganemaru, Shigehiro
AU - Kawai, Takayuki
AU - Fuchigami, Hirobumi
AU - Maeda, Naoyuki
AU - Koyama, Kumiko
AU - Kuboki, Yasutoshi
AU - Mukohara, Toru
AU - Doi, Toshihiko
AU - Yasunaga, Masahiro
N1 - Funding Information:
N.M. and K.K. are both employees of Daiichi Sankyo. T.K. and Y.K. received grants and research funding from Daiichi Sankyo. T.D. is a consultant/advisory board member for Daiichi Sankyo and received research funding from Daiichi Sankyo. M.Y. received research funding from Daiichi Sankyo. There are no potential conflicts of interest related to the other authors to disclose.
Funding Information:
We greatly thank Dr. Kogawa for enrolling and managing the patients. S.K. would like to thank Ms. Chihiro Morizono and Rumi Fujioka for IHC and IF experimental support. T.K. would like to thank Ms. Makiko Morita, Akiko Imasato, and Kaori Okada for support with LMD sampling and LDMS‐CE‐MS analysis. This work was financially supported by Daiichi‐Sankyo and a grant from the National Cancer Center Research and Development Fund (2020‐A‐9 to M.Y.).
Publisher Copyright:
© 2022 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
PY - 2022
Y1 - 2022
N2 - Background and Purpose: Intratumour heterogeneity frequently leads to drug resistance, which is a major issue in drug discovery. Drug distribution is one of the key factors for elucidating the resistance mechanism; however, quantitative and regional drug measurement is challenging. Here, we developed a novel ultra-sensitive analytical method and applied it to HER3-targeting antibody–drug conjugate patritumab deruxtecan (HER3-DXd), aiming to explore its payload (DXd) distribution within heterogeneous tissues. Experimental Approach: The developed analytical method is named LDMS-CE-MS, a capillary electrophoresis-mass spectrometry (CE-MS) coupled with a novel sample preconcentration/separation method called “large-volume dual-sample stacking by micelle collapse and sweeping (LDMS)”. First, the analytical performance of LDMS-CE-MS for DXd detection was evaluated. Subsequently, we evaluated the bystander effect of HER3-DXd, where tumour tissues were excised from xenograft models and clinical specimens after administration of HER3-DXd. HER3-high expression, adjacent, and HER3-low expression regions were then sampled by laser microdissection to quantify the released DXd. Key Results: LDMS concentrated DXd by 1000-fold and separated it from the hydrophilic bio-matrix through continuous capture and release by the charged micelles, allowing quantification at sub-attomole-level. DXd concentrations decreased in the order of antigen-high expression > adjacent > antigen-low expression regions in the tumour xenograft model, whereas in clinical specimens, adjacent and antigen-high expression regions had approximately the same concentration. These distributions represent a bystander effect. Conclusions and Implications: Our LDMS-CE-MS successfully visualized the attomole-level drug distributions in heterogeneous clinical specimens. This new platform opens a new era of quantitative pharmacokinetic analysis, facilitating drug discovery and development.
AB - Background and Purpose: Intratumour heterogeneity frequently leads to drug resistance, which is a major issue in drug discovery. Drug distribution is one of the key factors for elucidating the resistance mechanism; however, quantitative and regional drug measurement is challenging. Here, we developed a novel ultra-sensitive analytical method and applied it to HER3-targeting antibody–drug conjugate patritumab deruxtecan (HER3-DXd), aiming to explore its payload (DXd) distribution within heterogeneous tissues. Experimental Approach: The developed analytical method is named LDMS-CE-MS, a capillary electrophoresis-mass spectrometry (CE-MS) coupled with a novel sample preconcentration/separation method called “large-volume dual-sample stacking by micelle collapse and sweeping (LDMS)”. First, the analytical performance of LDMS-CE-MS for DXd detection was evaluated. Subsequently, we evaluated the bystander effect of HER3-DXd, where tumour tissues were excised from xenograft models and clinical specimens after administration of HER3-DXd. HER3-high expression, adjacent, and HER3-low expression regions were then sampled by laser microdissection to quantify the released DXd. Key Results: LDMS concentrated DXd by 1000-fold and separated it from the hydrophilic bio-matrix through continuous capture and release by the charged micelles, allowing quantification at sub-attomole-level. DXd concentrations decreased in the order of antigen-high expression > adjacent > antigen-low expression regions in the tumour xenograft model, whereas in clinical specimens, adjacent and antigen-high expression regions had approximately the same concentration. These distributions represent a bystander effect. Conclusions and Implications: Our LDMS-CE-MS successfully visualized the attomole-level drug distributions in heterogeneous clinical specimens. This new platform opens a new era of quantitative pharmacokinetic analysis, facilitating drug discovery and development.
UR - http://www.scopus.com/inward/record.url?scp=85144146250&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85144146250&partnerID=8YFLogxK
U2 - 10.1111/bph.15988
DO - 10.1111/bph.15988
M3 - Article
C2 - 36377519
AN - SCOPUS:85144146250
SN - 0007-1188
JO - British Journal of Pharmacology
JF - British Journal of Pharmacology
ER -